Market niche Immunostics operates in medical equipment manufacturing with a focus across oncology, women’s health, infectious disease, respiratory, and toxicology, indicating potential for cross-selling diagnostics across multiple high-demand therapeutic areas.

Recent expansion Historical acquisition by Boditech Med and active participation in regional pharma/diagnostics events (Medlab Middle East) suggest expanded market access and potential channel partnerships or distribution agreements in the Middle East and broader global markets.

COVID portfolio Launch of AFIAS COVID-19 Ab test and existing AFIAS analyzers imply a proven platform strategy that could be leveraged to upsell additional infectious disease and immunoassay products to current customers and labs seeking integrated solutions.

SME opportunities With 11-50 employees and revenue in the 1–10 million range, Immunostics presents a growth-ready environment for add-on partnerships, OEM collaborations, and sales of reagents, cartridges, and compatible analyzer consumables to scale with customer labs.

Technology fit Technology stack highlights include React and WordPress/Wix-based presence, suggesting flexibility for co-marketing, customer portal integrations, and streamlined eCommerce or distribution partnerships to accelerate product adoption and support.